Newsfile Corp
03 Sept 2026, 02:01 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Capricor Therapeutics is facing a class action lawsuit alleging it failed to disclose that the FDA had not agreed to changes in the statistical analysis plan for Deramiocel's clinical data. — Lack of FDA alignment on primary analysis plans significantly increases the risk of a Complete Response Letter (CRL) or regulatory rejection.
-0.80The lawsuit claims there is a substantial risk to the regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy. — For biotech firms, the failure of a lead candidate's regulatory approval can lead to a catastrophic loss of valuation.
-0.70A deadline of September 28, 2026, has been set for investors to move the Court to serve as lead plaintiff in the securities litigation. — While procedural, the formalization of lead plaintiffs advances the litigation process and maintains negative pressure on the stock.
-0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
Facing a securities class action lawsuit alleging misleading statements regarding FDA clinical data and regulatory approval risks for Deramiocel.
Mentioned as being subject to a securities class action lawsuit.
Mentioned as being subject to a securities class action lawsuit.
Mentioned as being the subject of a securities class action investigation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
2h ago
